Supplements > Special Issue: Payer/Provider Relationships in Oncology

Supplements - Special Issue: Payer/Provider Relationships in Oncology

May 20, 2011 – Sonya Blesser Streeter, MPP, MPH; Lee Schwartzberg, MD; Nadia Husain, ScM; and Michael Johnsrud, PhD
Ten percent of patients abandon newly initiated oral oncolytics at the pharmacy. Patients facing higher cost sharing or increased concurrent prescription activity have a higher abandonment rate.
May 22, 2011 – Xue Song, PhD; Zhongyun Zhao, PhD; Beth Barber, PhD; Christopher Gregory, BA; David Schutt, MD; and Sue Gao, PhD
This study characterized patterns and costs of medical care by disease phase in patients with newly diagnosed mCRC using a large US national commercially insured claims database.
May 21, 2011 – Francis X. Campion, MD, FACP; Leanne R. Larson, MHA; Pamela J. Kadlubek, MPH; Craig C. Earle, MD, MSc; and Michael N. Neuss, MD
The American Society of Clinical Oncology Quality Oncology Practice Initiative has grown to include 973 practices as of 2010. Practices demonstrated rates of end-of-life care and other measures of quality.
May 19, 2011 – J. Russell Hoverman, MD, PhD; Thomas H. Cartwright, MD; Debra A. Patt, MD, MPH; Janet L. Espirito, PharmD; Matthew P. Clayton; Jody S. Garey, PharmD; Terrance J. Kopp; Michael Kolodziej, MD; Marcus A.
Retrospective evaluations of electronic health records and claims databases to assess clinical outcomes and costs associated with evidence-based pathways in colon cancer.
May 20, 2011 – Sonya Blesser Streeter, MPP, MPH; Lee Schwartzberg, MD; Nadia Husain, ScM; and Michael Johnsrud, PhD
Ten percent of patients abandon newly initiated oral oncolytics at the pharmacy. Patients facing higher cost sharing or increased concurrent prescription activity have a higher abandonment rate.
May 21, 2011 – Francis X. Campion, MD, FACP; Leanne R. Larson, MHA; Pamela J. Kadlubek, MPH; Craig C. Earle, MD, MSc; and Michael N. Neuss, MD
The American Society of Clinical Oncology Quality Oncology Practice Initiative has grown to include 973 practices as of 2010. Practices demonstrated rates of end-of-life care and other measures of quality.
May 22, 2011 – Xue Song, PhD; Zhongyun Zhao, PhD; Beth Barber, PhD; Christopher Gregory, BA; David Schutt, MD; and Sue Gao, PhD
This study characterized patterns and costs of medical care by disease phase in patients with newly diagnosed mCRC using a large US national commercially insured claims database.
May 15, 2011 – Ted Okon, MBA, and Lee Schwartzberg, MD, FACP
With an increasing demand for cancer care driven by the demographics of the aging population far outpacing the supply of oncologists, and the ongoing transformation of the reimbursement system, the challenges facing oncology are formidable.
May 16, 2011 – Lee N. Newcomer, MD, MHA
Healthcare coverage is simply unaffordable for too many people. It will only become affordable with radical changes in payment incentives and elimination of care that doesn%u2019t really matter.
May 15, 2011 – Ted Okon, MBA, and Lee Schwartzberg, MD, FACP
With an increasing demand for cancer care driven by the demographics of the aging population far outpacing the supply of oncologists, and the ongoing transformation of the reimbursement system, the challenges facing oncology are formidable.
May 16, 2011 – Lee N. Newcomer, MD, MHA
Healthcare coverage is simply unaffordable for too many people. It will only become affordable with radical changes in payment incentives and elimination of care that doesn%u2019t really matter.
May 23, 2011 – John V. Cox, DO, MBA, FACP; and A. Mark Fendrick, MD
The editors introduce this special issue, which contributes to an ongoing dialogue in cancer care that explores the tension between new therapeutics and the ever-increasing need to limit resources.
May 23, 2011 – John V. Cox, DO, MBA, FACP; and A. Mark Fendrick, MD
The editors introduce this special issue, which contributes to an ongoing dialogue in cancer care that explores the tension between new therapeutics and the ever-increasing need to limit resources.
May 18, 2011 – Julia R. Trosman, PhD; Stephanie L. Van Bebber, MSc; and Kathryn A. Phillips, PhD
A study of major US private payers showed an important role and considerable shortcomings of external health technology assessment in coverage decisions on personalized medicine.
May 17, 2011 – Ilia L. Ferrusi, PhD(c); Natasha B. Leighl, MD; Nathalie A. Kulin, MSc; and Deborah A. Marshall, PhD
Economic evaluations of adjuvant trastuzumab were reviewed. Three primary shortcomings were identified including incorporation of local data and estimation and representation (visual) of decision uncertainty.
May 19, 2011 – J. Russell Hoverman, MD, PhD; Thomas H. Cartwright, MD; Debra A. Patt, MD, MPH; Janet L. Espirito, PharmD; Matthew P. Clayton; Jody S. Garey, PharmD; Terrance J. Kopp; Michael Kolodziej, MD; Marcus A.
Retrospective evaluations of electronic health records and claims databases to assess clinical outcomes and costs associated with evidence-based pathways in colon cancer.
May 18, 2011 – Julia R. Trosman, PhD; Stephanie L. Van Bebber, MSc; and Kathryn A. Phillips, PhD
A study of major US private payers showed an important role and considerable shortcomings of external health technology assessment in coverage decisions on personalized medicine.
May 17, 2011 – Ilia L. Ferrusi, PhD(c); Natasha B. Leighl, MD; Nathalie A. Kulin, MSc; and Deborah A. Marshall, PhD
Economic evaluations of adjuvant trastuzumab were reviewed. Three primary shortcomings were identified including incorporation of local data and estimation and representation (visual) of decision uncertainty.
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.